company background image
HLA

Healthia ASX:HLA Stock Report

Last Price

AU$1.47

Market Cap

AU$198.5m

7D

-6.7%

1Y

-20.5%

Updated

27 Sep, 2022

Data

Company Financials +
HLA fundamental analysis
Snowflake Score
Valuation6/6
Future Growth4/6
Past Performance0/6
Financial Health1/6
Dividends0/6

HLA Stock Overview

Healthia Limited provides health services in Australia.

Healthia Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Healthia
Historical stock prices
Current Share PriceAU$1.47
52 Week HighAU$2.44
52 Week LowAU$1.26
Beta1.66
1 Month Change-16.00%
3 Month Change4.63%
1 Year Change-20.54%
3 Year Change71.93%
5 Year Changen/a
Change since IPO23.01%

Recent News & Updates

Shareholder Returns

HLAAU HealthcareAU Market
7D-6.7%-3.7%-5.1%
1Y-20.5%-20.0%-11.9%

Return vs Industry: HLA matched the Australian Healthcare industry which returned -20% over the past year.

Return vs Market: HLA underperformed the Australian Market which returned -11.9% over the past year.

Price Volatility

Is HLA's price volatile compared to industry and market?
HLA volatility
HLA Average Weekly Movement6.3%
Healthcare Industry Average Movement5.2%
Market Average Movement9.7%
10% most volatile stocks in AU Market16.8%
10% least volatile stocks in AU Market4.3%

Stable Share Price: HLA is less volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: HLA's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2018n/aWes Cootehttps://www.healthia.com.au

Healthia Limited provides health services in Australia. It operates through three segments: Feet & Ankles; Bodies & Minds; and Eyes & Ears. The company operates podiatry, physiotherapy, hand therapy, occupational therapy, and speech pathology clinics; and retail footwear, optometry, and audiology stores, as well as manufactures and sells 3D printed orthotic devices for podiatry clinics.

Healthia Fundamentals Summary

How do Healthia's earnings and revenue compare to its market cap?
HLA fundamental statistics
Market CapAU$198.50m
Earnings (TTM)-AU$3.33m
Revenue (TTM)AU$200.29m

1.0x

P/S Ratio

-59.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
HLA income statement (TTM)
RevenueAU$200.29m
Cost of RevenueAU$147.45m
Gross ProfitAU$52.84m
Other ExpensesAU$56.17m
Earnings-AU$3.33m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.025
Gross Margin26.38%
Net Profit Margin-1.66%
Debt/Equity Ratio45.8%

How did HLA perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is HLA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HLA?

Other financial metrics that can be useful for relative valuation.

HLA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.9x
Enterprise Value/EBITDA11.7x
PEG Ration/a

Price to Sales Ratio vs Peers

How does HLA's PS Ratio compare to its peers?

HLA PS Ratio vs Peers
The above table shows the PS ratio for HLA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average1.2x
SLA SILK Laser Australia
1.4x6.1%AU$112.1m
AHX Apiam Animal Health
0.9x8.2%AU$138.7m
CAJ Capitol Health
1.8x8.4%AU$323.8m
ACL Australian Clinical Labs
0.7x-6.5%AU$718.9m
HLA Healthia
1x7.1%AU$198.5m

Price-To-Sales vs Peers: HLA is good value based on its Price-To-Sales Ratio (1x) compared to the peer average (1.2x).


Price to Earnings Ratio vs Industry

How does HLA's PE Ratio compare vs other companies in the AU Healthcare Industry?

Price-To-Sales vs Industry: HLA is good value based on its Price-To-Sales Ratio (1x) compared to the Australian Healthcare industry average (1.2x)


Price to Sales Ratio vs Fair Ratio

What is HLA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HLA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1x
Fair PS Ratio1.1x

Price-To-Sales vs Fair Ratio: HLA is good value based on its Price-To-Sales Ratio (1x) compared to the estimated Fair Price-To-Sales Ratio (1.1x).


Share Price vs Fair Value

What is the Fair Price of HLA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: HLA (A$1.47) is trading below our estimate of fair value (A$2.39)

Significantly Below Fair Value: HLA is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Future Growth

How is Healthia forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

4/6

Future Growth Score 4/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


28.5%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: HLA is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.8%).

Earnings vs Market: HLA is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: HLA is expected to become profitable in the next 3 years.

Revenue vs Market: HLA's revenue (7.1% per year) is forecast to grow faster than the Australian market (3.8% per year).

High Growth Revenue: HLA's revenue (7.1% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: HLA's Return on Equity is forecast to be low in 3 years time (11.2%).


Discover growth companies

Past Performance

How has Healthia performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


15.4%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: HLA is currently unprofitable.

Growing Profit Margin: HLA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: HLA is unprofitable, but has reduced losses over the past 5 years at a rate of 15.4% per year.

Accelerating Growth: Unable to compare HLA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: HLA is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (-7.9%).


Return on Equity

High ROE: HLA has a negative Return on Equity (0.2%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Healthia's financial position?

Financial Health Score

1/6

Financial Health Score 1/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: HLA's short term assets (A$27.5M) do not cover its short term liabilities (A$52.5M).

Long Term Liabilities: HLA's short term assets (A$27.5M) do not cover its long term liabilities (A$132.8M).


Debt to Equity History and Analysis

Debt Level: HLA's net debt to equity ratio (42.6%) is considered high.

Reducing Debt: Insufficient data to determine if HLA's debt to equity ratio has reduced over the past 5 years.

Debt Coverage: HLA's debt is well covered by operating cash flow (22.3%).

Interest Coverage: HLA's interest payments on its debt are not well covered by EBIT (1.8x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is Healthia current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage


3.96%

Forecast Dividend Yield

Dividend Yield vs Market

Healthia Dividend Yield vs Market
How does Healthia dividend yield compare to the market?
SegmentDividend Yield
Company (Healthia)0%
Market Bottom 25% (AU)2.8%
Market Top 25% (AU)7.1%
Industry Average (Healthcare)2.9%
Analyst forecast in 3 Years (Healthia)4.0%

Notable Dividend: Unable to evaluate HLA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate HLA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if HLA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if HLA's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: HLA is not paying a notable dividend for the Australian market.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as HLA has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.4yrs

Average management tenure


CEO

Wes Coote

3.42yrs

Tenure

AU$400,402

Compensation

Mr. Wesley James Coote, also known as Wes, B.Com., C.A., ACIS, serves as the Managing Director of Evolve Salons Limited. Mr. Coote has been Group Managing Director, Chief Executive Officer and Director at...


CEO Compensation Analysis

Wes Coote's Compensation vs Healthia Earnings
How has Wes Coote's remuneration changed compared to Healthia's earnings?
DateTotal Comp.SalaryCompany Earnings
Jun 30 2022n/an/a

-AU$3m

Mar 31 2022n/an/a

-AU$2m

Dec 31 2021n/an/a

AU$161k

Sep 30 2021n/an/a

AU$3m

Jun 30 2021AU$400kAU$306k

AU$5m

Mar 31 2021n/an/a

AU$6m

Dec 31 2020n/an/a

AU$7m

Sep 30 2020n/an/a

AU$5m

Jun 30 2020AU$313kAU$225k

AU$3m

Mar 31 2020n/an/a

AU$1m

Dec 31 2019n/an/a

AU$271k

Sep 30 2019n/an/a

-AU$483k

Jun 30 2019AU$226kAU$176k

-AU$1m

Compensation vs Market: Wes's total compensation ($USD259.77K) is about average for companies of similar size in the Australian market ($USD278.67K).

Compensation vs Earnings: Wes's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: HLA's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.


Board Members

Experienced Board: HLA's board of directors are considered experienced (4.3 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: HLA insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

ASX:HLA Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
16 Sep 22BuyAU$30,001Darren StewartIndividual20,409AU$1.47
16 Sep 22BuyAU$5,088Lisa DaltonIndividual3,461AU$1.47
16 Sep 22BuyAU$60,000Wesley CooteIndividual40,816AU$1.47
16 Sep 22BuyAU$750,002Glen RichardsIndividual510,205AU$1.47
16 Sep 22BuyAU$204,399Paul WilsonIndividual139,047AU$1.47
16 Sep 22BuyAU$59,976Lisa RoachIndividual40,800AU$1.47
01 Sep 22BuyAU$1,590,602MAM Pty LimitedCompany986,657AU$1.68
01 Sep 22BuyAU$2,190,317Wilson Asset Management (International) Pty LimitedCompany1,292,944AU$1.69
16 May 22BuyAU$8,088,580Moelis Australia Asset Management LtdCompany4,322,273AU$1.87
29 Apr 22BuyAU$195,540MAM Pty LimitedCompany107,350AU$1.99
29 Apr 22BuyAU$572,598Wilson Asset Management (International) Pty LimitedCompany317,589AU$1.80
17 Mar 22BuyAU$3,072,135MAM Pty LimitedCompany1,538,489AU$2.07
17 Mar 22BuyAU$6,193,467Wilson Asset Management (International) Pty LimitedCompany3,190,373AU$1.94
08 Mar 22BuyAU$36,411Paul WilsonIndividual20,000AU$1.94
04 Mar 22SellAU$52,115Darren StewartIndividual27,087AU$1.93
16 Dec 21BuyAU$63,790Anthony GanterIndividual37,393AU$2.25
19 Nov 21BuyAU$100,001Colin KangisserIndividual68,028AU$1.47
28 Sep 21BuyAU$66,856Wesley CooteIndividual37,142AU$1.80
28 Sep 21BuyAU$2,070,000Glen RichardsIndividual1,150,000AU$1.80
28 Sep 21BuyAU$14,373Lisa DaltonIndividual7,985AU$1.80

Ownership Breakdown

What is the ownership structure of HLA?
Owner TypeNumber of SharesOwnership Percentage
Private Companies8,486,2866.3%
Institutions24,350,22318.0%
Individual Insiders33,349,95024.7%
General Public68,848,85951.0%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.5%.


Top Shareholders

Top 25 shareholders own 49.01% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
6.79%
Moelis Australia Asset Management Ltd
9,165,154A$13.5m65.35%5.67%
5.94%
Darren Stewart
8,021,333A$11.8m0.26%no data
5.9%
Glen Richards
7,966,777A$11.7m6.84%no data
4.44%
Wilson Asset Management (International) Pty Limited
5,997,637A$8.8m27.48%0.44%
3.8%
Colin Kangisser
5,134,628A$7.5m0%no data
3.46%
MAM Pty Limited
4,672,787A$6.9m26.77%0.46%
3.21%
Chester Capital Investment Trust
4,333,400A$6.4m0%no data
3.13%
Viburnum Funds Pty Ltd.
4,232,346A$6.2m0%1.48%
2.98%
Dean Hartley
4,019,931A$5.9m0%no data
1.91%
Rom Group Pty Ltd
2,577,232A$3.8m0%no data
1.39%
Paul Wilson
1,877,129A$2.8m8%no data
1.28%
Wesley Coote
1,722,326A$2.5m2.43%no data
0.71%
Gregory Dower
962,317A$1.4m0%no data
0.69%
Anthony Ganter
938,222A$1.4m-18.86%no data
0.66%
Lisa Roach
895,819A$1.3m4.77%no data
0.6%
Zqn Pty Ltd
812,000A$1.2m0%no data
0.57%
Vassallo Corporate Holdings Pty Ltd
763,654A$1.1m0%no data
0.56%
Matthew Roach
757,267A$1.1m0%no data
0.3%
Gina Richman
404,665A$594.9k0%no data
0.3%
Christopher Angel
404,665A$594.9k0%no data
0.14%
Christopher Banks
192,270A$282.6k0%no data
0.14%
Dimensional Fund Advisors LP
182,299A$268.0k-0.03%no data
0.074%
Mandarine Gestion
100,000A$147.0k-33.33%no data
0.035%
Lisa Dalton
46,728A$68.7k8%no data
0.0043%
Katherine Baker
5,873A$8.6k0%no data

Company Information

Healthia Limited's employee growth, exchange listings and data sources


Key Information

  • Name: Healthia Limited
  • Ticker: HLA
  • Exchange: ASX
  • Founded: 2018
  • Industry: Health Care Services
  • Sector: Healthcare
  • Implied Market Cap: AU$198.502m
  • Shares outstanding: 135.04m
  • Website: https://www.healthia.com.au

Location

  • Healthia Limited
  • East Tower
  • Level 4
  • Bowen Hills
  • Queensland
  • 4006
  • Australia


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
HLAAFASX (Australian Securities Exchange)NPV DFD 07/10/22(EX-RIGHTS)AUAUDNo data
HLAASX (Australian Securities Exchange)YesOrdinary SharesAUAUDSep 2018
HLACHIA (Chi-X Australia)YesOrdinary SharesAUAUDSep 2018
HE3DB (Deutsche Boerse AG)YesOrdinary SharesDEEURSep 2018

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/27 00:00
End of Day Share Price2022/09/27 00:00
Earnings2022/06/30
Annual Earnings2022/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.